A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

• Status: RECRUITING
• Trial end date: 2027-03-01

Summary

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

• Phase: PHASE2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Astellas Pharma US, Inc.
• Treatments: enfortumab vedotin